Drug intelligence / Profile preview

CLS2901C

Development stage: Phase 3
Lead developer: CellSeed
Modality: Cell Therapies
Administration: Surgical, Intraarticular, Implantation

Overview

CLS2901C is an allogeneic cell therapy consisting of chondrocyte sheets developed by CellSeed. The sheets are produced using chondrocytes isolated from polydactyly-derived extra fingers, which are then cultured on temperature-responsive culture dishes to form a scaffold-free cell sheet. This regenerative medicine product is designed to treat cartilage defects and osteoarthritis of the knee (OAK) by promoting cartilage repair. It is typically used in conjunction with high tibial osteotomy (HTO) to improve clinical outcomes compared to surgery alone. The project has received funding from the Japan Agency for Medical Research and Development (AMED).

Other names: Allogeneic Chondrocyte Sheethuman allogenic chondrocyte sheets

Beyond the preview

Go deeper on CLS2901C.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CLS2901C.

Explore the full profile